An advisory panel to the FDA has recommended the approval of a new treatment option for use in postmenopausal women with osteoporosis and high fracture risk.
An advisory panel to the FDA has recommended the approval of a new treatment option for use in postmenopausal women with osteoporosis and high fracture risk.
The FDA has approved a selective serotonin-4 (5-HT4) receptor agonist to treat adults with chronic idiopathic constipation, a condition that affects 14% of the adult population.
The FDA has released a warning about the potential for an increase in disability in patients with multiple sclerosis who stop taking this immunosuppressant.